Nucleic acids encoding anti-VEGF-A antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-11634483-B2
Application number	US-202117152409-A
Country	US
Kind code	B2
Filing date	Jan 19, 2021
Priority date	Aug 23, 2016
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.

First claim

What is claimed is:

1. An isolated nucleic acid molecule comprising polynucleotides encoding an antibody comprising heavy chain complementarity determining regions 1-3 (HCDR1, HCDR2, and HCDR3) and light chain complementarity determining regions 1-3 (LCDR1, LCDR2, and LCDR3), wherein HCDR1, HCDR2, and HCDR3 and LCDR1, LCDR2, and LCDR3 comprise SEQ ID NOs: 79-84, respectively.

2. A vector comprising the nucleic acid molecule of claim 1 .

3. A cell comprising the vector of claim 2 .

4. A method of making an antibody comprising culturing a cell comprising the vector of claim 2 .

Assignees

• Medimmune Ltd

Inventors

• Leow Ching Ching
• Dimasi Nazzareno
• Coffman Karen
• Tsui Ping
• Gao Changshou
• Cepeda Mario A
• Schwartz Mittelman Adrian

Classifications

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K16/22 Primary

  against growth factors {; against growth regulators} · CPC title